Sarepta Therapeutics, INC Form 4 insider transactions

Sarepta Therapeutics' Chief Financial Officer, Ryan Ho-Yan Wong, received a grant of 118,875 restricted stock units, vesting over several years and tied to continued service and performance.

Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, received substantial restricted stock unit grants, aligning his incentives with long-term company performance.

Sarepta Therapeutics granted its EVP and General Counsel, Cristin Rothfuss, 118,875 restricted stock units, vesting over several years.

Sarepta Therapeutics' Chief Technology Operations Officer, Bilal Arif, was awarded 6,250 performance stock units, vesting in March 2026.

Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, earned 6,250 performance stock units based on company milestone achievements.

Sarepta Therapeutics' President of R&D and Tech Ops, Louise Rodino-Klapac, earned 6,250 performance stock units, which will vest in March 2026.

Sarepta Therapeutics' Chief Financial Officer, Ryan Ho-Yan Wong, disposed of 327 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Director Richard Barry exercised stock options and reported changes in beneficial ownership of Sarepta Therapeutics, Inc. shares.

Director Richard Barry reports exercising stock options and holding a significant amount of Sarepta Therapeutics stock.

Director Claude Nicaise exercised stock options and sold shares of Sarepta Therapeutics on March 12, 2025.

Director Deirdre P. Connelly reports acquisition of Sarepta Therapeutics stock and stock options.

Director Kathryn Boor reports acquisition and disposal of Sarepta Therapeutics common stock and stock options.

Director Michael Chambers reports acquisition and disposal of Sarepta Therapeutics common stock and stock options.

Chief Financial Officer Ian Michael Estepan of Sarepta Therapeutics reports transactions involving common stock, performance stock units, and stock options.

Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, reports the acquisition and disposal of company stock and stock options.

Director Hans Wigzell reports acquisition of Sarepta Therapeutics stock and stock options.

Director Stephen Mayo reports acquisition of Sarepta Therapeutics shares and stock options in a recent SEC filing.

Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports acquisition and disposal of company stock and stock options.

Chief Customer Officer Dallan Murray of Sarepta Therapeutics reports stock transactions including vesting of performance stock units, tax-related sales, and grant of restricted stock units and stock options.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports the vesting of performance stock units, tax-related stock sales, and the grant of restricted stock units.

Director Richard Barry reported acquiring shares and stock options in Sarepta Therapeutics on March 10, 2025.

Director Claude Nicaise reports acquisition of Sarepta Therapeutics stock and stock options.

Director M. Kathleen Behrens reports acquisition of common stock and stock options in Sarepta Therapeutics.

Chief Financial Officer of Sarepta Therapeutics, Ian Michael Estepan, reports the vesting of performance stock units and subsequent stock sales to cover tax obligations.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports the vesting of performance stock units and subsequent stock sales to cover tax obligations.

Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, reports disposals of common stock to cover tax withholding obligations related to vesting of PSUs and restricted stock units.

Chief Customer Officer Dallan Murray of Sarepta Therapeutics reports the vesting of performance stock units and subsequent stock sales to cover tax obligations.

Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports the vesting of performance stock units and subsequent stock sales to cover tax obligations.

EVP and General Counsel of Sarepta Therapeutics, Cristin Rothfuss, reports disposing of shares to cover tax withholding obligations related to vesting of restricted stock units.

Bilal Arif, Chief Tech Ops Officer of Sarepta Therapeutics, reports the disposal of common stock to cover tax withholding obligations related to vesting restricted stock units.